Elizabeth A. Garofalo - Jun 5, 2025 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
Director
Signature
/s/ Nathaniel Adams, Attorney-in-fact
Stock symbol
XENE
Transactions as of
Jun 5, 2025
Transactions value $
$0
Form type
4
Date filed
6/6/2025, 05:59 PM
Previous filing
Jun 2, 2025
Next filing
Jun 12, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
GAROFALO ELIZABETH A. Director 3650 GILMORE WAY, BURNABY, BRITISH COLUMBIA, CANADA /s/ Nathaniel Adams, Attorney-in-fact 2025-06-06 0001826361

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Share Option (Right to Buy) Award $0 +17K $0.00 17K Jun 5, 2025 Common Shares 17K $30.73 Direct F1
transaction XENE Restricted Share Units Award $0 +2.65K $0.00 2.65K Jun 5, 2025 Common Shares 2.65K $0.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders.
F2 Each restricted share unit represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders.